Efficacy of Brenipatide in Alcohol Use Disorder
Brenipatide demonstrates significant efficacy in promoting abstinence and reducing cravings in adults with alcohol use disorder.
In this seriesTopic Deep Dives5
What is the efficacy of brenipatide in maintaining abstinence in patients with alcohol use disorder?
Background
Alcohol use disorder (AUD) presents significant challenges in treatment, often leading to high relapse rates. Traditional pharmacotherapies can be inadequate for many patients.
Study Design
This multicenter, double-blind, placebo-controlled study included 452 participants diagnosed with moderate to severe AUD. The primary endpoint was the proportion of maintained abstinence over six months, validated by self-reported alcohol intake and biomarker levels.
Results Overview
Brenipatide (300 mg) administered monthly resulted in 68.1% of participants remaining abstinent. In contrast, only 39.8% in the placebo group reported the same.
Craving Severity and Quality of Life
Participants receiving brenipatide also saw significant reductions in craving severity scores and reported better quality of life overall.
Safety Profile
The compound showed a favorable safety profile with no serious adverse events linked to treatment, suggesting its viability as a long-term therapeutic option.
Conclusion
The findings indicate brenipatide as a promising new intervention in AUD treatment paradigms, bolstering the options available to practitioners.